Table 1.
Demographic and Clinical Characteristics of Study Population According to Cervical/Anal Dysplasia
| Characteristics | Population (n = 419) |
SIL+ (n = 214, 51%) |
SIL- (n = 205, 51%) |
P Values |
|---|---|---|---|---|
| Males, No. (%) | 303 (72.3) | 171 (79.9) | 132 (64.4) | <.0001 |
| Age, median (IQR), y | 42 (36–48) | 42 (36–48) | 43 (36–48) | .373 |
| Mode of HIV transmission, No. (%) | .001 | |||
| Homosexual contact | 209 (49.8) | 126 (60.3) | 83 (40.5) | |
| Heterosexual contact | 124 (29.6) | 55 (25.9) | 69 (33.7) | |
| IDU | 48 (11.5) | 15 (7.1) | 33 (16.1) | |
| Other/unknown | 38 (9.1) | 18 (7.5) | 20 (9.8) | |
| Syphilis coinfection, No. (%) | .001 | |||
| TPPA negative | 251 (59.9) | 111 (51.9) | 140 (68.6) | |
| TPPA positive | 131 (31.3) | 85 (39.7) | 46 (22.5) | |
| Unknown | 37 (8.8) | 18 (8.4) | 19 (8.8) | |
| HCV coinfection, No. (%) | .198 | |||
| Negative | 340 (81.1) | 175 (81.8) | 165 (80.5) | |
| HCV-Ab positive, RNA negative | 48 (11.5) | 21 (9.8) | 27 (13.2) | |
| HCV-Ab positive, RNA positive | 22 (5.3) | 15 (7) | 7 (3.4) | |
| Unknown | 9 (2.1) | 3 (1.4) | 6 (2.9) | |
| HBV coinfection, No. (%) | .914 | |||
| Negative | 291 (69.4) | 150 (70.1) | 141 (68.8) | |
| HBsAg positive | 11 (2.6) | 6 (2.8) | 5 (2.4) | |
| HBcAb positive | 105 (25.1) | 52 (24.3) | 53 (25.9) | |
| Unknown | 12 (2.9) | 6 (2.8) | 6 (2.9) | |
| AIDS-defining conditions, No. (%) | 86 (20) | 40 (21.4) | 46 (25.1) | .394 |
| Time since HIV diagnosis, median (IQR), mo | 88 (30–165) | 71 (20–151) | 95 (37–189) | .019 |
| Nadir CD4 + T-cell count, median (IQR), cells/mmc | 250 (144–358) | 260 (148–358) | 234 (128–355) | .583 |
| Pre-cART CD4/CD8 ratio | n = 250 0.35 (0.21–0.54) |
n = 138 0.36 (0.21–0.54) |
n = 112 0.34 (0.21–0.54) |
.913 |
| cART duration, median (IQR), mo | 43 (12–99.7) | 33 (9–92) | 49 (17–108) | .055 |
| cART regimen, No. (%) | .021 | |||
| PI-based | 133 (31.8) | 68 (31.8) | 65 (31.7) | |
| NNRTI-based | 167 (39.8) | 76 (35.5) | 91 (44.4) | |
| INSTI-based | 74 (17.8) | 49 (22.9) | 25 (12.2) | |
| Other | 41 (9.7) | 18 (8.4) | 23 (11.2) | |
| Unknown | 4 (0.9) | 3 (1.4) | 1 (0.5) | |
| Smoking history, No. (%) | .099 | |||
| Never smokers | 163 (38.9) | 81 (37.9) | 82 (40) | |
| Active smokers | 209 (49.9) | 114 (53.2) | 95 (46.3) | |
| Ex-smokers, quit >1 y ago | 39 (9.3) | 18 (8.4) | 21 (10.3) | |
| Unknown | 8 (1.9) | 1 (0.5) | 7 (3.4) |
Quantitative variables are presented as median (interquartile range), categorical variables as absolute number (percentage); P values were calculated by chi-square test or nonparametric Mann-Whitney test, as appropriate.
Abbreviations: Ab, antibody; cART, combination antiretroviral therapy; HBcAb, anti-HBV core antigen antibodies; HBsAg, hepatitis B surface antigen; HBV, hepatitis B virus; HCV, hepatitis C virus; HPV, human papillomavirus; IDU, intravenous drug users; INSTI, integrase strand transfer inhibitor; IQR, interquartile ranges; NNRTI, non-nucleoside reverse transcriptase inhibitor; PI, protease inhibitor; SIL, squamous intraepithelial lesion; TPPA, Treponema pallidum particle agglutination test.